MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…
  • 2025 International Congress

    Efficacy of LSVT-BIG Treatment Compared to Other Physiotherapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    A. Amin, M. Helal, A. Alsokery, H. Sabet, A. Ibrahim, A. Suleiman, I. Yakout, A. Abunamoos, M. Elsayed (Cairo, Egypt)

    Objective: We aim is to assess the efficacy of Lee Silverman Voice Treatment-BIG therapy (LSVT-BIG) compared to other physiotherapy in patients with Parkinson's Disease (PwP).…
  • 2025 International Congress

    Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

    F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

    Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…
  • 2025 International Congress

    Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…
  • 2025 International Congress

    Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States

    N. Crouse, C. Happel, M. Grall (Rockville, USA)

    Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…
  • 2025 International Congress

    The Effectiveness of Rivastigmine in Parkinson’s Disease: Impact on Motor Symptoms, Gait, Cognitive Function, and Falls – A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy of rivastigmine in patients with Parkinson’s disease (PD) by assessing its impact on motor symptoms, cognitive function, gait, falls, and…
  • 2025 International Congress

    VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

    M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

    Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
  • 2025 International Congress

    Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

    M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

    Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
  • 2025 International Congress

    A Multidimensional Biomarker Panel for The Early Detection of Parkinson’s Disease

    N. Shebl, S. Mowafi, A. Arafa, M. Wahid, M. Salama (Mansoura, Egypt)

    Objective: To explore the potential of a multidimensional biomarker panel integrating motor, non-motor, biochemical, metabolic, genetic, and neuroimaging biomarkers to increase sensitivity and specificity of…
  • 2025 International Congress

    Istradefylline for Freezing of Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the effects of istradefylline on motor function and freezing of gait (FOG) in patients with Parkinson’s disease (PD). Background: FOG is a…
  • « Previous Page
  • 1
  • …
  • 357
  • 358
  • 359
  • 360
  • 361
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley